Charta Aetatis Cyberpunk

Newsletter Pro Sign in Early access Register
Aa · Display
Themes
Type size
Density
MorningStar Security is in early access. The wiki is open to everyone; the news desks open with a code. Have a code, or want launch notice?
Export
growing · 2 feeds

mFLUSIVA

mRNA-based influenza vaccine for seniors approved by FDA

News volume 1 story in 90 days
23 Aug: 0 stories24 Aug: 0 stories25 Aug: 0 stories26 Aug: 0 stories27 Aug: 0 stories28 Aug: 0 stories29 Aug: 0 stories30 Aug: 0 stories31 Aug: 0 stories1 Sep: 0 stories2 Sep: 0 stories3 Sep: 0 stories4 Sep: 0 stories5 Sep: 0 stories6 Sep: 0 stories7 Sep: 0 stories8 Sep: 0 stories9 Sep: 1 story10 Sep: 0 stories11 Sep: 0 stories12 Sep: 0 stories13 Sep: 0 stories14 Sep: 0 stories15 Sep: 0 stories16 Sep: 0 stories17 Sep: 0 stories18 Sep: 0 stories19 Sep: 0 stories20 Sep: 0 stories21 Sep: 0 stories22 Sep: 0 stories23 Sep: 0 stories24 Sep: 0 stories25 Sep: 0 stories26 Sep: 0 stories27 Sep: 0 stories28 Sep: 0 stories29 Sep: 0 stories30 Sep: 0 stories1 Oct: 0 stories2 Oct: 0 stories3 Oct: 0 stories4 Oct: 0 stories5 Oct: 0 stories6 Oct: 0 stories7 Oct: 0 stories8 Oct: 0 stories9 Oct: 0 stories10 Oct: 0 stories11 Oct: 0 stories12 Oct: 0 stories13 Oct: 0 stories14 Oct: 0 stories15 Oct: 0 stories16 Oct: 0 stories17 Oct: 0 stories18 Oct: 0 stories19 Oct: 0 stories20 Oct: 0 stories21 Oct: 0 stories22 Oct: 0 stories23 Oct: 0 stories24 Oct: 0 stories25 Oct: 0 stories26 Oct: 0 stories27 Oct: 0 stories28 Oct: 0 stories29 Oct: 0 stories30 Oct: 0 stories31 Oct: 0 stories1 Nov: 0 stories2 Nov: 0 stories3 Nov: 0 stories4 Nov: 0 stories5 Nov: 0 stories6 Nov: 0 stories7 Nov: 0 stories8 Nov: 0 stories9 Nov: 0 stories10 Nov: 0 stories11 Nov: 0 stories12 Nov: 0 stories13 Nov: 0 stories14 Nov: 0 stories15 Nov: 0 stories16 Nov: 0 stories17 Nov: 0 stories18 Nov: 0 stories19 Nov: 0 stories20 Nov: 0 stories
Snapshot
Category
vaccine 1 source
Intelligence coverage

mFLUSIVA is an mRNA-based influenza vaccine developed by Moderna for seniors.

The vaccine leverages mRNA platform technology, representing an alternative to traditional egg-based influenza vaccine manufacturing. A key advantage of the mRNA approach is its significantly faster production timeline: mFLUSIVA can be manufactured in 1-2 months 1, compared to 6-8 months for conventional egg-based vaccines 1. This accelerated timeline potentially enables more rapid response to emerging influenza strains and seasonal demand.

Facts 2

AttributeValueConfidenceSourcesCited
Vendor Moderna low 1 1
Category vaccine low 1 1

Affected version 2

  • production timeline 1-2 months vs egg-based 6-8 months
  • approved for adults 50 and up

Platform 3

mRNAmRNA platformmRNA vaccine platform

Developed by 1

Official links

No official links recorded yet.
Work here? Claim this page with a verified company email or DNS record.

Frequently mentioned together 4

Sources 3

  1. Moderna's mRNA flu shot earns FDA approval after rollercoaster review · Ars Technica
  2. FDA Approves First mRNA Flu Shot · Slashdot
  3. The quick guide to fall vaccines and when you should get them · Ars Technica
That's Cyber for today

Tomorrow's desk, in your inbox by 06:00 UTC. The week's best stories, every Sunday. The month that mattered, on the 1st.

Drawn from the 519 sources the paper read this month. Text and HTML, one-click unsubscribe, free.

How often
Your desks